Tissue source site (TSS) for NCI's clinical proteomic tumor analysis consortium (CPTAC); 23 cases for payments 1-3. (23 cases @ $2,762.51 per case X 85%).

Ended Awarded Sep 17, 2018 Last action Jun 1, 2023

Contract number: 75N91018F00003
Awardee: Boston Medical Center Corporation UEI JZ8RQC4EMDZ5
Awarding agency: National Cancer Institute National Institutes of Health, Department of Health and Human Services
Obligated: $0

Award facts

Opportunity: N02CO5441602 Solicitation number

Full and Open Competition Tissue Purchase Order Acquisitions for NCI's Clinical Proteomic Tumor Analysis Consortium (CPTAC) Award Notice · Posted Jul 30, 2015
Contract value: $0.00 Current and potential, with all options
Completion date 100% complete: Sep 16, 2020 Current and potential, with all options
NAICS code: 325413 In-Vitro Diagnostic Substance Manufacturing
PSC: 6550 In Vitro Diagnostic Substances, Reagents, Test Kits And Sets
Set-aside: No set-aside
Competition: Competed under SAP · 1 offer Multiple Award, Fair Opportunity
Pricing: Firm Fixed Price
Place of performance: Roxbury, MA 02118, USA

Award details come from SAM.gov/FPDS.

Action	Obligated	Date
Supplemental Agreement for work within scope P00002 · Clinical proteomic tumor analysis consortium (CPTAC) imaging	-$66,024	Jun 1, 2023
Exercise an Option P00001 · Exercise option period 1 and fund additional cases for payments 1-3.	$12,017	Aug 30, 2019
Original award	$54,007	Sep 14, 2018

75N91018F00003 was awarded to Boston Medical Center Corporation by National Cancer Institute (National Institutes of Health) on September 17, 2018.

The government has obligated $0 on 75N91018F00003.

Yes. 75N91018F00003 is a delivery order under HHSN261201600011I, an indefinite delivery contract, on Tissue Source Site for Tumor Analysis.

The extent of competition for 75N91018F00003 was competed under sap. The government received 1 offer.

On GovTribe

Try for free Login